What an oncologist wants us to know about everyday chemicals
Host Elahe Izadi speaks with oncologist Dr. Mikkael Sekeres about the connection between endocrine disruptors and cancer. Dr. Sekeres also shares his advice on steps he takes to avoid these chemicals–and how he puts the risks into perspective.
Today's show was produced by Thomas Lu, with help from Rennie Svirnovskiy, who also mixed the episode. It was edited by Ariel Plotnick.
Subscribe to The Washington Post here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya's Chief Executive Officer, will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025 at 11:30 am ET. The live webcast of the fireside chat may be accessed from the Investors section of Tenaya's website. An archived replay will be available on the Tenaya website for approximately 30 days following the live event. About Tenaya TherapeuticsTenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya's pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) and TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Tenaya has employed a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of novel medicines based on genetic insights, including TN-301, a clinical-stage small molecule HDAC6 inhibitor for the potential treatment of heart failure and related cardio/muscular disease, and multiple early-stage programs in preclinical development aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit Tenaya ContactsMichelle CorralVP, Corporate Communications and Investor RelationsIR@ InvestorsAnne-Marie FieldsPrecision AQ in to access your portfolio
Medscape
15 minutes ago
- Medscape
Does Getting Fit Guard Against Colorectal Cancer?
Evidence continues to mount that building cardiovascular fitness can help lower an individual's risk for colorectal cancer (CRC). The latest study — a sweeping analysis of 643,583 individuals, with more than 8000 cases of CRC and 10 years follow-up — found a consistent, inverse, and graded association between cardiorespiratory fitness (CRF) and the risk for the development of CRC — a benefit similar for men and women and across races. CRC risk was 9% lower for each 1-metabolic equivalent (MET) task increase in CRF, objectively measured by an exercise treadmill test. When assessed across CRF categories, there was a progressive decline in CRC risk with higher CRF, Aamir Ali, MD, and colleagues with Veterans Affairs Medical Center, Washington, DC, found. Compared with the least fit individuals (METs, 4.8), the CRC risk was 14% lower in those falling in the low-fit CRF category (METs, 7.3), 27% lower for moderately fit people (METs, 8.6), 41% lower for fit individuals (METs, 10.5), and 57% lower for high-fit individuals (METs, 13.6). Moderate CRF is attainable by most middle-aged and older individuals, by engaging in moderate-intensity physical activity such as brisk walking, which aligns with current national guidelines, the authors said. The study was published online on July 28 in Mayo Clinic Proceedings. The results dovetail with earlier work. For example, in the Cooper Center Longitudinal Study, men with high mid-life CRF had a 44% lower risk for CRC and a 32% lower risk of dying from cancer later in life men with low CRF. A recent meta-analysis for the World Cancer Research Fund estimated a 16% lower risk for colon cancer in people with the highest levels of recreational physical activity relative to those with the lowest levels. A recent UK Biobank analysis using accelerometers linked higher daily movement to a 26% reduction in risk across multiple cancers, including bowel cancer. Taken together, the data suggest that 'the more you exercise, the better your overall health is going to be — not just your cardiac fitness but also your overall risk of cancer,' Joel Saltzman, MD, medical oncologist at Cleveland Clinic Taussig Cancer Center, Cleveland, noted in an interview with Medscape Medical News . Can You Outrun CRC Risk? In the US, CRC is the second leading cause of cancer mortality, accounting for 51,896 deaths in 2019. The economic burden of CRC in the US is significant, topping $24 billion annually. And while the incidence of colon cancer has decreased in older individuals during the past 3 decades, the incidence in younger adults has nearly doubled during the same period, 'underscoring the limitations of screening programs and the critical need for risk factor modification,' Ali and colleagues wrote. 'There is good evidence that exercise and healthy lifestyle/diet have significant benefit overall and as well for some potential risk reduction for colon cancer,' David Johnson, MD, professor of medicine and chief of gastroenterology, Eastern Virginia Medical School in Norfolk, Virginia, told Medscape Medical News. 'There are clearly suggestions of why this makes sense via the beneficial effects of exercise and physical activity in CRC pathways including but not limited to regulation of inflammation and aberrant cell growth/cancer pathways,' Johnson said. He emphasized, however, that exercise and lifestyle are not the best way to prevent CRC. 'Appropriate screening, in particular by colonoscopy (by skilled physicians who meet high-quality performance national benchmarks) to detect and remove precancerous polyps, is the best approach for prevention,' Johnson said. 'At this point — albeit exercise is potentially helpful and a great general recommendation — my most current advice as an expert in the field, is that you cannot outrun CRC risk,' Johnson said. Can You Outrun CRC Recurrence? Prevention aside, the data thus far are even more supportive of risk reduction for patients who have had CRC and are targeting reduction of recurrence, Johnson said. Perhaps the most compelling study was recently published in The New England Journal of Medicine. The CHALLENGE trial enrolled patients with resected stage II or III colon cancer who had completed their adjuvant chemotherapy. Patients with recurrences within a year of diagnosis were excluded, as they were more likely to have highly aggressive, biologically active disease. Participants were randomized to receive healthcare education materials alone or in conjunction with a structured exercise program over a 3-year follow-up period. The focus of the exercise intervention was increasing recreational aerobic activity over baseline by at least 10 METs — essentially the equivalent of adding about 45-60 minutes of brisk walking or 25-30 minutes of jogging three to four times a week. At a median follow-up of nearly 8 years, exercise reduced the relative risk for disease recurrence, new primary cancer, or death by 28% ( P = .02). 'This benefit persisted — and even strengthened — over time, with disease-free survival increasing by 6.4 and 7.1 percentage points at 5 and 8 years, respectively,' Johnson noted in a Medscape commentary. The CHALLENGE results are 'very compelling,' Bishal Gyawali, MD, PhD, associate professor of oncology at Queen's University, Kingston, Ontario, Canada, noted in a separate Medscape commentary. 'If you compare these results with results from other trials, you'll see that this is a no-brainer. If this were a drug, you would want to use it today,' Gyawali said. Saltzman told Medscape Medical News patients often ask him what they can do to help prevent their cancer from coming back. 'I would sort of say, 'Well, eat a healthy diet and exercise,' but I didn't have a lot of good evidence to support it.' The CHALLENGE study provides 'the proof in the pudding.' With these strong data, 'it almost feels like I should be able to write a prescription for my patient to join an exercise program and that their insurance should cover it,' Saltzman said.
Medscape
15 minutes ago
- Medscape
ED Use Before Cancer Tied to Higher Mortality
TOPLINE: In a matched cohort study of 410,120 patients with cancer, emergency department (ED) visits within 90 days before diagnosis were associated with a significantly increased risk for mortality, and the elevated risk persisted through 7 years of follow-up. METHODOLOGY: Researchers conducted a retrospective study of 410,120 adults diagnosed with cancer between 2014 and 2021 in Ontario, Canada, with follow-up until death, 7 years, or March 31, 2024. A total of 205,060 patients who had ED visits in the 90 days before cancer diagnosis were matched 1:1 with patients without such visits, based on sex, year of diagnosis, and propensity scores. The primary outcome was all-cause mortality. TAKEAWAY: Overall mortality was 61.7% in patients with ED use vs 37.8% in those without ED use; the risk remained consistently higher among patients with ED use across all timepoints. The elevated risk for mortality among patients with ED use was highest at 30 days (hazard ratio [HR], 4.49; 95% CI, 4.40-4.58) and remained significant over 7 years (HR at 7 years, 1.05; 95% CI, 1.01-1.09). Patients hospitalized at the ED visit had a higher risk for mortality at all timepoints (HR at 30 days, 5.83; 95% CI, 5.69-5.99; HR at 7 years, 1.30; 95% CI, 1.23-1.37). Additionally, discharged patients had a higher risk for mortality up to 3 years (HR at 30 days, 2.68; 95% CI, 2.59-2.77; HR at 3 years, 1.38; 95% CI, 1.34-1.41; HR at 7 years, 1.03; 95% CI, 0.98-1.10), but the association was not significant for follow-up beyond 3 years. IN PRACTICE: Higher risk for mortality among patients presenting to the ED prior to cancer diagnosis emphasizes the need for "established systems of care to ensure timely cancer workup for patients with suspected cancer in the ED" and "health care system improvements to enhance early cancer detection and management, thereby reducing the reliance on emergency care for initial cancer presentations," the study authors wrote. SOURCE: The study was led by Keerat Grewal, MD, MSc, Schwartz/Reisman Emergency Medicine Institute, Sinai Health, Toronto, Ontario, Canada, and was published online on July 22, 2025, in JAMA Network Open. LIMITATIONS: Unrelated ED visits may have been included. The observational design limited causal inference. The cancer stage at diagnosis and race and ethnicity were not accounted for. DISCLOSURES: The study was supported by Canadian Institutes of Health Research and ICES, which is funded by the Ontario Ministry of Health and the Ministry of Long-Term Care. One author reported receiving a salary from ICES outside the submitted work. Several authors reported receiving research grants or personal fees or serving as experts for various organizations.
